

INFORMAZIONI PERSONALI **Rossi Daniela**

POSIZIONE RICOPERTA **Medico responsabile di Struttura  
CMID-Struttura Divisionale di Reumatologia del  
Centro di Eccellenza per le Malattie Reumatologiche, Immunologiche,  
Nefrologiche e Rare dell'Ospedale Hub San Giovanni Bosco di Torino  
Membro, per la Regione Piemonte, del Network delle Eccellenze Europee per le  
Malattie Reumatologiche rare e complesse (ERN- econnet).**

ESPERIENZA  
PROFESSIONALE

Responsabile della SS Reumatologia dell'Ospedale G. Bosco e della gestione dei farmaci biotecnologici del Centro di Eccellenza per le Malattie Reumatologiche, Immunologiche, Nefrologiche e Rare dell'Ospedale Hub San Giovanni Bosco di Torino

Si tratta di una Struttura organizzata secondo il modello Europeo della Rete delle Eccellenze Europee per le malattie rare e complesse del Connettivo (ERN-Reconnet)

E' stata relatrice in numerosissimi Congressi nazionali e internazionali ed ha al suo attivo una vasta produzione scientifica

E' stata membro del Comitato Scientifico di tutti i Congressi di *Patologia Immune e Malattie Orfane organizzati dal CMID* (e giunto quest'anno alla sua 28° edizione).

## ISTRUZIONE E FORMAZIONE

3/11/93	Laurea in Medicina e Chirurgia <i>Università degli Studi di Torino</i>
11/1998	Specializzazione in Patologia Clinica (punteggio di 70/70 e lode) <i>Università degli Studi di Torino</i>
11/2006	Specializzazione in Allergologia ed Immunologia Clinica (70/70 e lode) <i>Università degli Studi di Catania</i>
03/2012	Specializzazione in Reumatologia (punteggio 70/70 e lode) <i>Università degli Studi di Catania</i>
09/2001	Diploma di Ecodoppler <i>Ospedale Orsola Malpighi – Med. Int. - Bologna</i>
12/2001	Corso di Ecografia Clinica

02-03/2002	Medicina d'Urgenza - Osp. G. Bosco - Torino Corso di Formazione Manageriale per Direttori e Coordinatori di Dipartimento. SDA Bocconi - Milano
12/ 2002 e 2003	Corsi di Videocapillaroscopia Divisione Reumatologia - Osp. Murri- Jesi
09/2008	Corso di Ecografia muscolo-scheletrica Universita' La Sapienza di Roma
09/2012	Corso teorico-pratico sulla diagnosi e trattamento dell'AR
03/2014	Corso di base Ecografia clinica in emergenza- urgenza – ASLT02
11/2018	Corso di ecografia extrarticolare nell'AR
11/2019	Corso di ecografia extrarticolare in Reumatologia

## COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

Inglese

COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
Ascolto	Letture	Interazione	Produzione orale	
B2	C1	B1	B1	B1
Sostituire con il nome del certificato di lingua acquisito. Inserire il livello, se conosciuto				

 Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato  
 Quadro Comune Europeo di Riferimento delle Lingue

Competenze organizzative e gestionali

Responsabile di Struttura da oltre 15 anni

- Docenze
- Docente per insegnamento di Patologia e diagnostica di Laboratorio, modulo di Patologia Clinica e Medicina trasfusionale nell'ambito del Corso di Laurea in Infermieristica ASL di Torino.
  - Già Docente di Reumatologia presso il Corso di Laurea della Professione Sanitaria di Tecnico di Laboratorio Medico
  - Docente della Scuola di Specializzazione di Patologia Clinica dell'Università di Torino.
  - Segretario Scientifico e Docente del Master di Reumatologia Pratica (Università di Torino)
  - Docente del Master sulle Malattie Rare Università di Torino)
  - Già Docente del Master di Allergologia e Immunologia Pediatrica.
  - Presidente del Corso di Capillaroscopia nell'ambito del Convegno su "Patologia Immune e Malattie Orfane" a Torino.

Abilitazioni nazionali Professore di II fascia di Reumatologia (settore concorsuale 06/d3)

Patente di guida Patente B

---


#### ULTERIORI INFORMAZIONI

PUBBLICAZIONI  
**77 pubblicazioni censite su PubMed**

Torino, 3.12.24

Daniela Rossi

## Publicazioni dr.ssa Daniela Rossi



1: Roccatello D, Sciascia S, De Simone E, Schindler T, Martins E, Mao HA, Rossi D, Fenoglio R. Extremely Long-Lasting B-cell Depletion and BAFFling Effects Following Obinutuzumab-Based Regimen in Lupus Nephritis. *Kidney Int Rep.* 2024 Aug 10;9(10):3079-3080. doi: 10.1016/j.ekir.2024.08.008. PMID: 39430193; PMCID: PMC11489493.

2: Pozzato M, Parodi G, Rossi D, Stasi E, Roccatello D. Fitwalking: A New Frontier for Kidney Patients - A Center's Experience. *Kidney Blood Press Res.* 2024;49(1):443-456. doi: 10.1159/000539525. Epub 2024 May 28. PMID: 38801816.

3: Foddai SG, Radin M, Cecchi I, Rubini E, Barinotti A, Alba P, Gimén Alonso C, Rossi D, Roccatello D, Sciascia S. 2023 ACR/EULAR classification criteria in existing research cohorts: an International study. *Rheumatology (Oxford).* 2024 Oct 1;63(10):2770-2775. doi: 10.1093/rheumatology/keae058. PMID: 38290789.

4: Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, Rubini E, Rossi D, De Simone E, Del Vecchio G, Cozzi M, Sciascia S. Daratumumab monotherapy for refractory lupus nephritis. *Nat Med.* 2023 Aug;29(8):2041-2047. doi: 10.1038/s41591-023-02479-1. Epub 2023 Aug 10. PMID: 37563241; PMCID: PMC10427415.

5: Radin M, Cecchi I, Barinotti A, Wilson Jones G, Arbrile M, Miraglia P, Mahler M, Bentow C, Rossi D, Menegatti E, Roccatello D, Sciascia S. Identifying subsets of patients with undifferentiated connective tissue disease: Results from a prospective, real-world experience using particle-based multi-analyte technology. *Autoimmun Rev.* 2023 May;22(5):103298. doi: 10.1016/j.autrev.2023.103298. Epub 2023 Feb 14. PMID: 36796708.

6: Roccatello D, Sciascia S, Rossi D, Fenoglio R. Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management. *Drugs.* 2023 Feb;83(2):117-134. doi: 10.1007/s40265-022-01824-x. Epub 2023 Feb 2. PMID: 36729344.

7: Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, Mancardi D, Wilson Jones G, Rossi D, Roccatello D. Renal Fibrosis in Lupus Nephritis. *Int J Mol Sci.* 2022 Nov 18;23(22):14317. doi: 10.3390/ijms232214317. PMID: 36430794; PMCID: PMC9699516.

8: Sciascia S, Radin M, Cecchi I, Barinotti A, Rubini E, Rossi D, Fenoglio R, Vaccarino A, Menegatti E, Roccatello D. Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol. *Clin Exp Rheumatol.* 2023 Mar;41(3):597-604. doi: 10.55563/clinexprheumatol/qa2yb4. Epub 2022 Oct 28. PMID: 36305361.

9: Radin M, Rubini E, Cecchi I, Foddai SG, Barinotti A, Rossi D, Sciascia S, Roccatello D. Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. *Clin Exp Rheumatol.* 2023 Jan;41(1):197. doi: 10.55563/clinexprheumatol/g1a1u3. Epub 2022 Oct 13. PMID: 36227692.

10: Roccatello D, Sciascia S, Naretto C, Barreca A, Solfietti L, Battaglia L, Viziello L, Fenoglio R, Rossi D. Recognizing the new disorder "idiopathic hypocryoglobulinaemia" in patients with previously unidentified clinical conditions. *Sci Rep.* 2022 Sep 1;12(1):14904. doi: 10.1038/s41598-022-18427-x. PMID: 36050335; PMCID: PMC9437023.

11: Arbrile M, Radin M, Rossi D, Menegatti E, Roccatello D, Sciascia S. Pregnancy outcomes in Behçet's disease: Results from a monocentric cohort. *J Reprod Immunol.* 2022 Sep;153:103682. doi: 10.1016/j.jri.2022.103682. Epub 2022 Aug 1. PMID: 35963078.

12: Sciascia S, Barinotti A, Radin M, Cecchi I, Menegatti E, Terzolo E, Rossi D, Baldovino S, Fenoglio R, Roccatello D. Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. *J Clin Med.* 2022 May 25;11(11):2977. doi: 10.3390/jcm11112977. PMID: 35683365; PMCID: PMC9181809.

13: Radin M, Arbrile M, Cecchi I, Di Nunzio P, Buccarano N, Di Gregorio F, Milone V, Osella S, Crosasso P, Favuzzi MD, Barinotti A, Baldovino S, Menegatti E, Rossi D, Sciascia S, Roccatello D. Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. *Int J Environ Res Public Health.* 2022 Apr 28;19(9):5379. doi: 10.3390/ijerph19095379. PMID: 35564772; PMCID: PMC9102425.

14: Fenoglio R, Sciascia S, Rossi D, Naretto C, Alpa M, Roccatello D. Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab. *Front Med (Lausanne).* 2022 Mar 28;9:819320. doi: 10.3389/fmed.2022.819320. PMID: 35419372; PMCID: PMC8995745.

15: Roccatello D, Sciascia S, Murgia S, Quattrocchio G, Ferro M, De Simone E, Naretto C, Barreca A, Sammartino A, Rossi D, Fenoglio R. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy. *Front Immunol.* 2022 Mar 24;13:777134. doi: 10.3389/fimmu.2022.777134. PMID: 35401565; PMCID: PMC8988143.

16: Arbrile M, Radin M, Rossi D, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. *Front Immunol.* 2021 Oct 25;12:769785. doi: 10.3389/fimmu.2021.769785. PMID: 34759935; PMCID: PMC8573273.

17: Perrone F, Piccirillo MC, Ascierio PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bontanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gergiuolo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. *J Transl Med.* 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. Erratum for: *J Transl Med.* 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. PMID: 34674735; PMCID: PMC8529863.

18: Radin M, Rubini E, Cecchi I, Foddal SG, Barinotti A, Rossi D, Sciascia S, Roccatello D. Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. *Clin Exp Rheumatol.* 2022 Mar;40(3):575-580. doi: 10.55563/clinexprheumatol/7vp1bo. Epub 2021 Jun 26. PMID: 34251309.



19: Roccatello D, Sciascia S, Fenoglio R, Rossi D. A new challenge for lupus nephritis management: Induction therapy without immunosuppressive maintenance regimen. *Autoimmun Rev.* 2021 Jul;20(7):102844. doi: 10.1016/j.autrev.2021.102844. Epub 2021 May 7. PMID: 33971336.

20: Roccatello D, Sciascia S, Naretto C, Alpa M, Fenoglio R, Ferro M, Quattrocchio G, Rubini E, Rahbani E, Rossi D. A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. *Kidney Int Rep.* 2021 Feb 3;6(4):1081-1087. doi: 10.1016/j.ekir.2021.01.027. PMID: 33912758; PMCID: PMC8071649.

21: Rossi D, Cecchi I, Sciascia S, Naretto C, Alpa M, Roccatello D. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. *Clin Exp Rheumatol.* 2021 Mar-Apr;39 Suppl 129(2):125-128. doi: 10.55563/clinexprheumatol/l0hd9v. Epub 2021 Feb 23. PMID: 33635228.

22: Sciascia S, Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Vaccarino A, Rossi D, Roccatello D. Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. *Front Med (Lausanne).* 2021 Feb 1;8:621590. doi: 10.3389/fmed.2021.621590. PMID: 33598471; PMCID: PMC7882486.

23: Rossi D, Sciascia S, Cecchi I, Saracco M, Montabone E, Modena V, Pellerito R, Carignola R, Roccatello D. A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. *J Clin Med.* 2021 Jan 14;10(2):292. doi: 10.3390/jcm10020292. PMID: 33466837; PMCID: PMC7830314.

24: Rossi D, Sciascia S, Fenoglio R, Ferro M, Baldovino S, Kamgaing J, Ventrella F, Kalikatzaros I, Viziello L, Solfietti L, Barreca A, Roccatello D.

Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. *Minerva Med.* 2021 Apr;112(2):162-174. doi: 10.23736/S0026-4806.20.07076-7. Epub 2020 Nov 16. PMID: 33198442.

25: Perrone F, Piccirillo MC, Ascierio PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Mulesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. *J Transl Med.* 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. Erratum in: *J Transl Med.* 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. PMID: 33087150; PMCID: PMC7576974.

26: Roccatello D, Fenoglio R, Naretto C, Baldovino S, Sciascia S, Ferro M, Rossi D. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. *J Clin Med.* 2020 Oct 9;9(10):3232. doi: 10.3390/jcm9103232. PMID: 33050272; PMCID: PMC7600836.

27: Roccatello D, Fenoglio R, Baldovino S, Naretto C, Ferro M, Barreca A, Rossi D, Sciascia S. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis. *Autoimmun Rev.* 2020

Sep;19(9):102622. doi: 10.1016/j.autrev.2020.102622. Epub 2020 Jul 12. PMID: 32663622.

28: Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. *Int J Mol Sci.* 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129. PMID: 32531894; PMCID: PMC7312896.

29: Fenoglio R, Baldovino S, Ferro M, Sciascia S, Rabajoli G, Quattrocchio G, Beltrame G, Naretto C, Rossi D, Alpa M, Barreca A, Papotti MG, Roccatello D. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. *J Nephrol.* 2021 Feb;34(1):231-240. doi: 10.1007/s40620-020-00748-7. Epub 2020 May 29. PMID: 32472525.

30: Sciascia S, Radin M, Cecchi I, Di Nunzio P, Buccarano N, Di Gregorio F, Valeria M, Osella S, Crosasso P, Favuzzi MD, Rubini E, Foddai SG, Baldovino S, Roccatello D, Rossi D. Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study. *Int J Environ Res Public Health.* 2020 May 15;17(10):3469. doi: 10.3390/ijerph17103469. PMID: 32429245; PMCID: PMC7277549.

31: Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol.* 2020 May-Jun;38(3):529-532. Epub 2020 May 1. PMID:

32359035.

32: Sciascia S, Radin M, Cecchi I, Fenoglio R, De Marchi A, Besso L, Baldovino S, Rossi D, Miraglia P, Rubini E, Roccatello D. Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. *J Nephrol*. 2020 Aug;33(4):757-762. doi: 10.1007/s40620-019-00698-9. Epub 2020 Jan 23. PMID: 31974856.

33: Sciascia S, Radin M, Cecchi I, Bertolaccini ML, Bertero MT, Rubini E, Vaccarino A, Bazzan M, Giachino O, Baldovino S, Rossi D, Mengozzi G, Roccatello D. Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. *Rheumatology (Oxford)*. 2021 Mar 2;60(3):1106-1113. doi: 10.1093/rheumatology/kez596. PMID: 31840749.

34: Sciascia S, Cecchi I, Massara C, Rossi D, Radin M, Ladehesa PL, Guñazu F, Rubini E, Foddai SG, Alba P, Escudero A, Menegatti E, Roccatello D. Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. *Autoimmun Rev*. 2020 Feb;19(2):102449. doi: 10.1016/j.autrev.2019.102449. Epub 2019 Dec 12. PMID: 31838167.

35: Rossi D, Sciascia S, Roccatello D. Nailfold Capillaroscopy Patterns. *Isr Med Assoc J*. 2019 Jul;21(7):497-498. PMID: 31507129.

36: Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. *Ann Rheum Dis*. 2018 Nov;77(11):1694-1695. doi: 10.1136/annrheumdis-2018-213496. Epub 2018 May 18. PMID: 29776976.

37: Roccatello D, Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Sandrone M, Radin M, Baldovino S, Menegatti E. Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. *Lupus*. 2018 Jul;27(8):1393-1394. doi: 10.1177/0961203317751645. Epub 2018 Jan 11. PMID: 29325491.

38: Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Fenoglio R, Baldovino S, Menegatti E. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. *Oncotarget*. 2017 May 23;8(32):52072-52077. doi: 10.18632/oncotarget.18120. PMID: 28881714; PMCID: PMC5581013.

39: Rossi D, Zanatta E, Marson P, Sciascia S, Polito P, Roccatello D, Cozzi F. How I treat patients with systemic sclerosis in clinical practice. *Autoimmun Rev*. 2017 Oct;16(10):1024-1028. doi: 10.1016/j.autrev.2017.07.018. Epub 2017 Aug 1. PMID: 28778710.

40: Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Barreca A, Fenoglio R, Baldovino S, Menegatti E. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. *Am J Nephrol*. 2017;46(2):108-113. doi: 10.1159/000477944. Epub 2017 Jul 13. PMID: 28700988.

41: Roccatello D, Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Baldovino S, Menegatti E. Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. *BMJ Open*. 2017 Jun 21;7(6):e015243. doi: 10.1136/bmjopen-2016-015243. PMID: 28637732; PMCID: PMC5734246.

42: Roccatello D, Sciascia S, Rossi D, Solfietti L, Fenoglio R, Menegatti E,



Baldovino S. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. *Oncotarget*. 2017 Jun 20;8(25):41764-41777. doi: 10.18632/oncotarget.16986. PMID: 28454112; PMCID: PMC5522247.

43: Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Menegatti E. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. *Am J Nephrol*. 2016;43(4):251-60. doi: 10.1159/000445841. Epub 2016 Apr 29. PMID: 27161362.

44: Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. *Autoimmun Rev*. 2015 Dec;14(12):1123-30. doi: 10.1016/j.autrev.2015.07.017. Epub 2015 Aug 2. PMID: 26244817.

45: Rossi D, Modena V, Sciascia S, Roccatello D. Rheumatoid arthritis: Biological therapy other than anti-TNF. *Int Immunopharmacol*. 2015 Aug;27(2):185-8. doi: 10.1016/j.intimp.2015.03.019. Epub 2015 Mar 31. PMID: 25840282.

46: Garrino L, Picco E, Finiguerra I, Rossi D, Simone P, Roccatello D. Living with and treating rare diseases: experiences of patients and professional health care providers. *Qual Health Res*. 2015 May;25(5):636-51. doi: 10.1177/1049732315570116. Epub 2015 Feb 9. PMID: 25667160.

47: Taruscio D, Kodra Y, Ferrari G, Vittozzi L; National Rare Diseases Registry Collaborating Group. The Italian National Rare Diseases Registry. *Blood*

Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s606-13. doi: 10.2450/2014.0064-14s.  
PMID: 24922301; PMCID: PMC4044798.

48: Rossi D, Russo A, Manna E, Binello G, Baldovino S, Sciascia S, Roccatello D.  
The role of nail-videocapillaroscopy in early diagnosis of scleroderma.  
Autoimmun Rev. 2013 Jun;12(8):821-5. doi: 10.1016/j.autrev.2012.11.006. Epub  
2012 Dec 4. PMID: 23219768.

49: Sciascia S, Piras D, Baldovino S, Russo A, Naretto C, Rossi D, Alpa M,  
Roccatello D. Mycophenolate mofetil as steroid-sparing treatment for elderly  
patients with giant cell arteritis: report of three cases. Aging Clin Exp Res.  
2012 Jun;24(3):273-7. doi: 10.1007/BF03325257. PMID: 23114555.

50: Sciascia S, Roccatello D, Bertero MT, Di Simone D, Cosseddu D, Vaccarino A,  
Bazzan M, Rossi D, Garcia-Fernandez C, Ceberio L, Stella S, Menegatti E,  
Baldovino S. 8-isoprostane, prostaglandin E2, C-reactive protein and serum  
amyloid A as markers of inflammation and oxidative stress in antiphospholipid  
syndrome: a pilot study. Inflamm Res. 2012 Aug;61(8):809-16. doi:  
10.1007/s00011-012-0468-0. Epub 2012 May 26. PMID: 22638905.

51: Sciascia S, Roccatello D, Rossi D, Russo A, Mereuta MO, Cavallo R. High-  
titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome. J Rheumatol.  
2012 Apr;39(4):871-3. doi: 10.3899/jrheum.110873. PMID: 22467952.

52: Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing  
treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011  
Sep;38(9):2080-1. doi: 10.3899/jrheum.110496. PMID: 21885526.

53: Sciascia S, Bazzan M, Baldovino S, Vaccarino A, Rossi D, Russo A, Roccatello

D. Antiphospholipid syndrome and relapsing polychondritis: an unusual association. *Lupus*. 2011 Oct;20(12):1336-7. doi: 10.1177/0961203311409270. Epub 2011 Jul 22. PMID: 21784779.

54: Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Russo A, Menegatti E, Baldovino S. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. *Am J Nephrol*. 2011;34(2):175-80. doi: 10.1159/000329535. Epub 2011 Jul 8. PMID: 21757891.

55: Roccatello D, Rossi D, Marletto F, Naretto C, Sciascia S, Baldovino S, Piras D, Giachino O. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. *J Nephrol*. 2012 Mar-Apr;25(2):198-203. doi: 10.5301/JN.2011.8452. PMID: 21725921.

56: Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. *Lupus*. 2011 Oct;20(10):1106-8. doi: 10.1177/0961203311400115. Epub 2011 Jun 7. PMID: 21652607.

57: Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. *Nephrol Dial Transplant*. 2011 Dec;26(12):3987-92. doi: 10.1093/ndt/gfr109. Epub 2011 Mar 8. PMID: 21385860.

58: Menegatti E, Davit A, Francica S, Berardi D, Rossi D, Baldovino S, Tovo PA, Sena LM, Roccatello D. Genetic factors associated with rheumatoid arthritis and



systemic vasculitis: Evaluation of a panel of polymorphisms. *Dis Markers*. 2009;27(5):217-23. doi: 10.3233/DMA-2009-0666. PMID: 20037209; PMCID: PMC3835025.

59: Naretto C, Baldovino S, Rossi E, Spriano M, Roccatello D. The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab. *Lupus*. 2009 Aug;18(9):856-7. doi: 10.1177/0961203309103053. PMID: 19578113.

60: Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, Cavallo R, Giachino O. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. *Clin Exp Rheumatol*. 2008 May-Jun;26(3 Suppl 49):S67-71. PMID: 18799057.

61: Alpa M, Ferrero B, Cavallo R, Naretto C, Menegatti E, Di Simone D, Napoli F, La Grotta R, Rossi D, Baldovino S, Sena LM, Roccatello D. Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. *Autoimmun Rev*. 2008 Oct;8(1):56-8. doi: 10.1016/j.autrev.2008.07.027. Epub 2008 Aug 12. PMID: 18703170.

62: Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, Napoli F, Sena LM. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. *Clin Rev Allergy Immunol*. 2008 Feb;34(1):111-7. doi: 10.1007/s12016-007-8019-0. PMID: 18270864.

63: Alpa M, Ferrero B, Cavallo R, Perna A, Naretto C, Gennaro M, Di Simone D, Bellizia L, Mansouri M, Rossi D, Modena V, Giachino O, Sena LM, Roccatello D. Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus

